Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by invest2profiton Feb 18, 2021 1:26pm
216 Views
Post# 32597128

Re-read the last NR

Re-read the last NR"With market clearance obtained, 2020 was a very successful and foundational year for Yutian's marketing efforts in China. It successfully installed the QAS in the hospitals of the top three medical universities in Anhui province as well as leading hospitals in the cities of Shanghai (one of the four direct-administered municipalities with 27 million people), Hangzhou (capital city of Zhejiang province with 57 million people), Wenzhou and Zhengzhou (capital city of Henan province with 94 million people). A total of eight QAS machines are currently operational in China.

In addition, Yutian has appointed Tier 1 distributors in major regions throughout China and is currently setting sales targets for 2021."
<< Previous
Bullboard Posts
Next >>